Insider Selling: Progyny (NASDAQ:PGNY) CFO Sells 2,139 Shares of Company Stock

Key Points

• CFO Mark Livingston sold 2,139 Progyny shares for $64,170 at an average price of $30, leaving him with 70,314 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
• Progyny reported quarterly earnings of $0.52 per share, beating the $0.31 consensus estimate; revenue reached $341.25 million, up 8.9% year over year.
• Analysts maintain a generally positive outlook: the stock has a “Moderate Buy” consensus rating and a $34.92 average price target, with some brokerages recently raising targets.

Progyny, Inc. (NASDAQ:PGNY - Get Free Report) CFO Mark Livingston sold 2,139 shares of the company's stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $30.00, for a total transaction of $64,170.00. Following the completion of the transaction, the chief financial officer owned 70,314 shares of the company's stock, valued at approximately $2,109,420. This trade represents a 2.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Stock Up 1.4%

Shares of PGNY stock traded up $0.47 during trading hours on Friday, hitting $34.84. 1,420,642 shares of the company's stock traded hands, compared to its average volume of 1,365,733. The stock has a market cap of $2.67 billion, a PE ratio of 31.96, a price-to-earnings-growth ratio of 2.08 and a beta of 0.97. The stock's 50 day simple moving average is $27.27 and its 200 day simple moving average is $24.54. Progyny, Inc. has a 12 month low of $16.10 and a 12 month high of $35.50.

Progyny (NASDAQ:PGNY - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.21. The company had revenue of $341.25 million for the quarter, compared to analysts' expectations of $340.76 million. Progyny had a net margin of 6.80% and a return on equity of 19.23%. Progyny's revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.15 earnings per share. As a group, equities research analysts expect that Progyny, Inc. will post 1.25 EPS for the current fiscal year.

Institutional Trading of Progyny

Hedge funds have recently bought and sold shares of the business. Public Employees Retirement System of Ohio purchased a new stake in shares of Progyny during the 2nd quarter worth approximately $29,000. Nykredit A S purchased a new position in shares of Progyny during the 2nd quarter valued at $38,000. IFP Advisors Inc grew its stake in shares of Progyny by 376.0% during the 2nd quarter. IFP Advisors Inc now owns 1,961 shares of the company's stock worth $57,000 after acquiring an additional 1,549 shares during the period. Toth Financial Advisory Corp bought a new position in shares of Progyny during the 2nd quarter worth $65,000. Finally, Integrated Wealth Concepts LLC purchased a new stake in Progyny in the 2nd quarter worth about $74,000. Institutional investors and hedge funds own 94.93% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have commented on PGNY. Cantor Fitzgerald upped their price target on shares of Progyny from $31.00 to $35.00 and gave the company an "overweight" rating in a research report on Thursday. Weiss Ratings upgraded Progyny from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday, October 8th. Canaccord Genuity Group set a $35.00 target price on Progyny in a research report on Friday, August 7th. Citigroup reiterated a "market outperform" rating on shares of Progyny in a report on Thursday. Finally, BTIG Research lifted their target price on Progyny from $30.00 to $40.00 and gave the stock a "buy" rating in a report on Friday, July 24th. Eleven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $34.92.

Progyny News Summary

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny reported third-quarter earnings of $0.52 per share and revenue of $341.25 million, slightly above the cited consensus revenue estimate. Revenue grew 8.9% year over year, while earnings increased from $0.15 per share a year earlier. Read More.
• Positive Sentiment: The company raised its full-year 2026 earnings guidance, a sign that management sees stronger earnings prospects. Read More.
• Positive Sentiment: Several analysts raised their price targets following the results: Citizens JMP and Leerink Partners moved to $38, while Cantor Fitzgerald raised its target to $35 and maintained an overweight rating. These revisions reinforce a favorable analyst view, although the targets imply varying degrees of potential upside. Read More.
• Neutral Sentiment: Coverage highlighted new client wins and margin expansion, but also noted a cautious market response. This suggests investors may be weighing growth and profitability improvements against expectations already reflected in the stock. Read More.

Progyny Company Profile

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.